Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

<div>(a) Zone I disease prior to the bevacizumab injection: female infant, BW 2050 g, GA 28 w, treated with intravitreal bevacizumab at PMA of 34 weeks and PNA of 6 weeks. (b) The same case as in (a), 8 weeks after the intravitreal injection of bevacizumab showing ROP regression.</div>

Journal of Ophthalmology

fig2

Figure 2

Figure 2: Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity 

Figure 2 | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity 